YOKOHAMA, Japan, July 28, 2026
AGC Biologics has signed a long-term commercial manufacturing agreement valued at hundreds of millions of dollars with a major international pharmaceutical company, securing half of the mammalian manufacturing capacity at its new Yokohama, Japan, facility before the site officially begins operations. The landmark agreement covers five commercial biologics programs and demonstrates the increasing global demand for geopolitically stable biopharmaceutical manufacturing hubs capable of supporting worldwide regulatory approvals and reliable supply chains. Under the multi-year contract, AGC Biologics will manufacture a minimum of 35 commercial batches annually, providing end-to-end services that include process transfer, process scale-up, regulatory validation, and commercial manufacturing. The products manufactured at the Yokohama site will support regulatory submissions to major global agencies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The agreement represents a significant milestone for AGC Biologics as it expands its global CDMO network while reinforcing Japan’s growing strategic role in resilient biologics manufacturing.
Commercial Partnership Strengthens Global Biologics Supply Chain
The newly announced manufacturing partnership highlights the pharmaceutical industry’s continued shift toward diversified and geopolitically secure supply chains for the production of complex biologic medicines. Under the agreement, AGC Biologics will dedicate a substantial portion of its new Yokohama manufacturing facility to support the undisclosed pharmaceutical company’s commercial biologics portfolio through a multi-year manufacturing commitment. The project includes comprehensive technology transfer, scale-up activities, process performance qualification (PPQ) campaigns, regulatory validation, and long-term commercial production. Four PPQ campaigns are expected to be completed during the first two years of operation, ensuring readiness for regulatory inspections and global product launches. By selecting Japan as its commercial manufacturing base, the customer gains access to a highly trusted pharmaceutical manufacturing environment that minimizes geopolitical, regulatory, and trade-related risks while ensuring consistent global supply for patients. The agreement further reflects increasing industry confidence in Japan as a strategic manufacturing hub for high-value biologics serving international markets.
Advanced Yokohama Facility Expands Manufacturing Capacity
Scheduled to become operational in 2027, AGC Biologics’ new Yokohama facility will significantly expand the company’s global manufacturing network through advanced single-use bioprocessing technologies. The facility will include four 2,000-liter Cytiva single-use bioreactors and two 5,000-liter Thermo Fisher Scientific DynaDrive single-use bioreactors, adding a total of 18,000 liters of flexible mammalian manufacturing capacity. Beyond commercial biologics production, the site will provide cell therapy development and GMP manufacturing, supported by six clean rooms, alongside messenger RNA (mRNA) development and manufacturing capabilities equipped with dedicated in vitro transcription (IVT), purification, and lipid nanoparticle (LNP) production lines. The facility has been designed to support multiple advanced therapeutic modalities while enabling rapid scale-up for global commercialization. Company leadership emphasized that securing a major commercial customer before construction is completed demonstrates strong market confidence in both the Yokohama facility and AGC Biologics’ proven expertise in delivering high-quality biologics manufacturing solutions.
Advertisement
Investment Reinforces Japan’s Growing CDMO Leadership
The Yokohama expansion forms part of Japan’s strategic biomanufacturing investment program launched by the Ministry of Economy, Trade and Industry (METI) to strengthen domestic biologics production capacity and reinforce the country’s position as a trusted manufacturing partner for allied nations. AGC Biologics brings extensive global manufacturing experience to the new site, including more than 30 years of GMP manufacturing expertise, 100 successful regulatory inspections, over 30 commercial biologic products launched, and more than 100 regulatory approvals across international markets. The company has also supported the development and manufacturing of over 400 products for more than 250 customers through its cGMP manufacturing network spanning North America, Europe, and Japan. According to AGC Biologics leadership, the combination of advanced manufacturing technology, regulatory excellence, and Japan’s stable business environment positions the Yokohama facility as a critical component of future global biologics supply chains. As demand for reliable outsourced manufacturing continues to increase, the new agreement strengthens AGC Biologics’ leadership as a premier Contract Development and Manufacturing Organization (CDMO) supporting the commercialization of next-generation biopharmaceutical products worldwide.
Source: AGC Biologics press release
